Taiwan · Delayed Price · Currency is TWD SCI Pharmtech Statistics
Total Valuation
SCI Pharmtech has a market cap or net worth of TWD 6.87 billion. The enterprise value is 7.42 billion.
| Market Cap | 6.87B |
| Enterprise Value | 7.42B |
Important Dates
The last earnings date was Monday, September 8, 2025.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | Jul 1, 2025 |
Share Statistics
SCI Pharmtech has 119.51 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Current Share Class | 119.51M |
| Shares Outstanding | 119.51M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 0.59% |
| Float | 69.80M |
Valuation Ratios
The trailing PE ratio is 14.20.
| PE Ratio | 14.20 |
| Forward PE | n/a |
| PS Ratio | 4.42 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 6.62 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.50, with an EV/FCF ratio of -105.33.
| EV / Earnings | 15.38 |
| EV / Sales | 4.78 |
| EV / EBITDA | 18.50 |
| EV / EBIT | 48.40 |
| EV / FCF | -105.33 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.23 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 2.06 |
| Debt / FCF | -12.88 |
| Interest Coverage | 40.87 |
Financial Efficiency
Return on equity (ROE) is 9.25% and return on invested capital (ROIC) is 1.92%.
| Return on Equity (ROE) | 9.25% |
| Return on Assets (ROA) | 1.73% |
| Return on Invested Capital (ROIC) | 1.92% |
| Return on Capital Employed (ROCE) | 3.20% |
| Revenue Per Employee | 6.50M |
| Profits Per Employee | 2.02M |
| Employee Count | 239 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 1.86 |
Taxes
In the past 12 months, SCI Pharmtech has paid 88.20 million in taxes.
| Income Tax | 88.20M |
| Effective Tax Rate | 15.45% |
Stock Price Statistics
The stock price has decreased by -34.51% in the last 52 weeks. The beta is -0.06, so SCI Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -34.51% |
| 50-Day Moving Average | 59.94 |
| 200-Day Moving Average | 74.29 |
| Relative Strength Index (RSI) | 39.01 |
| Average Volume (20 Days) | 126,730 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCI Pharmtech had revenue of TWD 1.55 billion and earned 482.50 million in profits. Earnings per share was 4.05.
| Revenue | 1.55B |
| Gross Profit | 393.90M |
| Operating Income | 191.89M |
| Pretax Income | 570.70M |
| Net Income | 482.50M |
| EBITDA | 437.40M |
| EBIT | 191.89M |
| Earnings Per Share (EPS) | 4.05 |
Balance Sheet
The company has 358.60 million in cash and 907.19 million in debt, giving a net cash position of -548.59 million or -4.59 per share.
| Cash & Cash Equivalents | 358.60M |
| Total Debt | 907.19M |
| Net Cash | -548.59M |
| Net Cash Per Share | -4.59 |
| Equity (Book Value) | 5.38B |
| Book Value Per Share | 44.89 |
| Working Capital | 237.39M |
Cash Flow
In the last 12 months, operating cash flow was 1.04 billion and capital expenditures -1.11 billion, giving a free cash flow of -70.45 million.
| Operating Cash Flow | 1.04B |
| Capital Expenditures | -1.11B |
| Free Cash Flow | -70.45M |
| FCF Per Share | -0.59 |
Margins
Gross margin is 25.36%, with operating and profit margins of 12.36% and 31.07%.
| Gross Margin | 25.36% |
| Operating Margin | 12.36% |
| Pretax Margin | 36.75% |
| Profit Margin | 31.07% |
| EBITDA Margin | 28.17% |
| EBIT Margin | 12.36% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 2.60%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 2.60% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 30.96% |
| Buyback Yield | -3.06% |
| Shareholder Yield | -0.46% |
| Earnings Yield | 7.02% |
| FCF Yield | -1.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 27, 2023. It was a forward split with a ratio of 1.125.
| Last Split Date | Jul 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.125 |
Scores
SCI Pharmtech has an Altman Z-Score of 4.44 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.44 |
| Piotroski F-Score | 6 |